ASTERDM

- Aster DM Quality Care Limited's subsidiary acquired a 14.21% stake in STS Holdings Limited, a Bangladesh-based healthcare company, for USD 44,114,339. The acquisition aligns with a Merger Framework Agreement and enhances business in healthcare services. STS Holdings Limited reported a turnover of BDT 10,534.24 Million for the year ended 31 March 2026.

- Postal Ballot Notice for shareholder approval of governance changes. - Key proposals: Appointment of new MD & Group CEO Mr. Varun Shadilal Khanna, six other Non-Executive/Independent Directors, revised remuneration for Executive Chairman & Executive Director, and approval of Aster DM Quality Care Limited Employee Stock Option Scheme 2026.

- Trading approval received for 35,35,51,410 Equity Shares of ₹10/- each, allotted pursuant to the Scheme of Amalgamation. - These shares will be listed and available for trading on BSE and NSE from August 17, 2026.

- Q1 FY27 Consolidated Proforma Revenue ₹2,597Cr vs ₹2,164Cr (▲20% YoY) - EBITDA ₹576Cr vs ₹443Cr (▲30% YoY) - EBITDA Margin 22.2% vs 20.5% (▲170bps) - Management targets 24-25% EBITDA margin in the next 2-3 years and anticipates 10-15% incremental EBITDA from merger synergies. - Plans to add over 4,170 beds in the next 3-4 years, increasing total capacity to over 15,000 beds.

- Video/Audio recording of the earnings call for the quarter ended June 30, 2026, held on August 5, 2026, is available on Aster DM Quality Care Limited's website.

- Analyst/Investors Meet Schedule - Event: Non-deal Roadshow organized by Kotak Mahindra Capital Company Limited - Date: 10th August 2026 to 14th August 2026 - Time: Business hours (9:00 AM to 6 PM IST/SGT) - Mode: Virtual and In-Person (Mumbai and Singapore)

- Board meeting on 05 August 2026 approved the Notice of Postal Ballot and 18th Annual General Meeting (scheduled for 28 September 2026). - Termination of operations and management agreement for Aster G. Madegowda Hospital due to sustained operating losses (0.15% of revenue). - Acquisition of up to an additional 12% equity stake in subsidiary United CIIGMA Institute of Medical Sciences Private Limited (UCIMSPL) for up to ₹40.93 crores.

- Board approved terminating operations for Aster G. Madegowda Hospital due to sustained losses (0.15% of revenue). - Approved acquiring up to 12% additional stake in subsidiary United CIIGMA Institute of Medical Sciences for up to ₹40.93 Cr. - Also approved Postal Ballot and 18th AGM on 28 September 2026.

- Consolidated Revenue ₹2,597 Cr (▲20% YoY) - EBITDA ₹576 Cr (▲30% YoY) - EBITDA Margin 22.2% vs 20.5% (▲170bps)

- Consolidated Revenue ₹1,310.68 Cr vs ₹1,077.87 Cr (▲21.60% YoY) - EBITDA ₹141.55 Cr vs ₹197.25 Cr (▼28.24% YoY) - PAT ₹29.28 Cr vs ₹93.56 Cr (▼68.71% YoY) - EBITDA Margin 10.80% vs 18.30% (▼750 bps) - The quarter included an exceptional expense of ₹114.38 Cr related to merger costs. Profit before exceptional items and tax grew by 37.05% YoY to ₹200.85 Cr.